{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:12:24Z","timestamp":1781824344776,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaad.2025.09.123","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:10:29Z","timestamp":1767744629000},"page":"1438-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["To test or not to test? Revisiting the value of baseline screening and monitoring tests among biologic treatments for psoriasis using an evidence-based assessment"],"prefix":"10.1016","volume":"94","author":[{"given":"Jessica Q.","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon J.","family":"Razler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Hrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","article-title":"Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review","volume":"20","author":"Snast","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.123_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1179\/2295333714Y.0000000043","article-title":"Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection","volume":"69","author":"De Keyser","year":"2014","journal-title":"Acta Clin Belg"},{"issue":"17","key":"10.1016\/j.jaad.2025.09.123_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.2023.3954","article-title":"Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force","volume":"329","author":"Jonas","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis \u2013 time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2025.09.123_bib7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib8","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/jdv.19406","article-title":"No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients","volume":"38","author":"Manzanares","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.123_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/jdv.14146","article-title":"Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature","volume":"31","author":"Piaserico","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.123_bib11","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/jdv.14300","article-title":"Reply: Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature","volume":"31","author":"Ricceri","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.123_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Invest"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.123_bib13","doi-asserted-by":"crossref","first-page":"e1203","DOI":"10.1111\/jdv.19186","article-title":"Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: a multicentric retrospective cohort study of 49 patients","volume":"37","author":"Ciolfi","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.123_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.123_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta dermato-venereologica"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","article-title":"Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study","volume":"85","author":"Chiu","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2475530320954279","article-title":"Biologic treatment of 4 HIV-positive patients: a case series and literature review","volume":"6","author":"Myers","year":"2021","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.123_bib19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/jdv.19020","article-title":"The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: a real-world cohort study","volume":"37","author":"Xu","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjd.13004","article-title":"Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice","volume":"171","author":"Shear","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bjd\/ljac040","article-title":"Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials","volume":"188","author":"Langley","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjd.19314","article-title":"Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2025.09.123_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.123_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.36849\/JDD.2020.5337","article-title":"The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2)","volume":"19","author":"Menter","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.123_bib27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/jdv.12296","article-title":"Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis","volume":"28","author":"Wu","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2014.08.050","article-title":"OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results","volume":"72","author":"Kimball","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-Term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjd.17084","article-title":"Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis","volume":"180","author":"Leonardi","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.123_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2220447","article-title":"Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest","volume":"34","author":"Egeberg","year":"2023","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.09.123_bib36","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta dermato-venereologica"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-023-01074-z","article-title":"Risk of cutaneous T cell lymphoma with psoriasis biologic therapies","volume":"14","author":"Davis","year":"2024","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2025.09.123_bib42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"New Engl J Med"},{"issue":"10273","key":"10.1016\/j.jaad.2025.09.123_bib45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.jaad.2025.09.123_bib46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator\u2013controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.123_bib48","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-Term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"10.1016\/j.jaad.2025.09.123_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.12788\/cutis.0088","article-title":"Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis","volume":"106","author":"Lee","year":"2020","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/apt.15370","article-title":"Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease","volume":"50","author":"Korzenik","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.123_bib56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.18329","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.123_bib57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.123_bib58","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s13555-022-00743-9","article-title":"Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure","volume":"12","author":"Griffiths","year":"2022","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.123_bib59","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.jaad.2025.09.123_bib60","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.123_bib61","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib62","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaad.2020.04.010","article-title":"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors","volume":"83","author":"Wright","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.123_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15794","article-title":"Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study","volume":"35","author":"Diotallevi","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.123_bib64","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1111\/jdv.17175","article-title":"Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?","volume":"35","author":"Piaserico","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.123_bib66","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41395-018-0372-5","article-title":"Trick or TREAT? More safety data of infliximab during pregnancy","volume":"113","author":"Kane","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.123_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatology"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.123_bib69","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1111\/jdv.15671","article-title":"Psoriasis and pregnancy outcomes in biological therapies: a real-life, multi-centre experience","volume":"33","author":"Odorici","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.123_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14931","article-title":"Considerations on inhibition of IL-23 in psoriatic women of childbearing potential","volume":"34","author":"Russo","year":"2021","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.123_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","article-title":"Managing psoriasis in patients with HBV or HCV infection: practical considerations","volume":"20","author":"Piaserico","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.123_bib72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jdv.15878","article-title":"Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ","volume":"34","author":"Masson Regnault","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.123_bib73","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:07:53Z","timestamp":1776406073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0190962226000022"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.123","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To test or not to test? Revisiting the value of baseline screening and monitoring tests among biologic treatments for psoriasis using an evidence-based assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}